Skip to main content
Clinical Trials/NCT02034539
NCT02034539
Unknown
Phase 2

Prospektive, Randomisierte Und Kontrollierte Studie Zum Einfluss Des VADOplex-Systems Auf Die Lebensqualität im Rahmen Der Behandlung Der Chronisch-kritischen Extremitätenischämie im Stadium IV Nach Fontaine

Asklepios Kliniken Hamburg GmbH1 site in 1 country38 target enrollmentOctober 2013

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Peripheral Artery Disease
Sponsor
Asklepios Kliniken Hamburg GmbH
Enrollment
38
Locations
1
Primary Endpoint
wound healing
Last Updated
12 years ago

Overview

Brief Summary

In patients with critical limb ischemia (CLI) and foot ulcers wound healing is an important goal which can normally only be achieved after sufficient treatment of the underlying ischemia (revascularization either by an operation, e. g. bypass, or a catheter intervention). After successful revascularization everything should be done to improve wound healing because this regularly takes weeks up to several months. One possibility to speed up healing could be treatment with the VADOplex device which delivers an automatic intermittent painless compression of the sole of the foot thereby increasing perfusion of the leg. This system can be easily operated by patients themselves and at home.

Our goal is to prove that the VADOPlex system accelerates healing up and improves quality of life.

Registry
clinicaltrials.gov
Start Date
October 2013
End Date
November 2014
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Claas Luedemann

Claas Luedemann, MD

Asklepios Kliniken Hamburg GmbH

Eligibility Criteria

Inclusion Criteria

  • signed informend consent
  • peripheral artery disease Fontaine IV (equals Ruterford 5 and 6) with or without neuropathy
  • foot lesion stage 1 - 4 analogous to 4 Wagner classification of the diabetic foot
  • secondary wound healing if previous surgical wound treatment
  • previous interventional and/or surgical revascularisation
  • age above 18
  • hosptalized to the beginning of the study

Exclusion Criteria

  • primary wound healing if previous surgical wound treatment
  • uncontrolled local or systemic infection
  • renal failure on dialysis
  • inability or insufficient help to operate the VADOplex system
  • wound dressings that lead to insufficient compression by the VADOplex system (e.g. total contact cast for offloading)
  • wounds of other than ischemic or neuro-ischemic origin

Outcomes

Primary Outcomes

wound healing

Time Frame: at discharge, 2 weeks, 4 weeks, 8 weeks, 12 weeks and 24 weeks after discharge

complete healing of the target lesion

change of quality of life

Time Frame: at discharge, 2 weeks, 4 weeks, 8 weeks, 12 weeks and 24 weeks after discharge

change of quality of life compared to baseline. Quality of life measured with the EQ-5D tool (European quality of life in 5 dimensions)

Secondary Outcomes

  • time to complete wound healing(at discharge, 2 weeks, 4 weeks, 8 weeks, 12 weeks and 24 weeks after discharge)
  • Wound size(at discharge, 2 weeks, 4 weeks, 8 weeks, 12 weeks and 24 weeks after discharge)
  • change of pain intensity(at discharge, 2 weeks, 4 weeks, 8 weeks, 12 weeks and 24 weeks after discharge)
  • change of ankle-brachial index(at discharge, 2 weeks, 4 weeks, 8 weeks, 12 weeks and 24 weeks after discharge)
  • incidence of deep vein thrombosis(24 weeks after discharge or whenever a thrombosis is suspected)

Study Sites (1)

Loading locations...

Similar Trials